title: Cucurbitacins - a promising target for cancer therapy.
abstract: During the last decades a large number of cucurbitacins have been isolated from various plant species belonging to other plant families than Cucurbitaceae. Although the roots and the fruits of plant belong to these Cucurbitaceae species are very bitter, they have been used as folk medicines in some countries because of their wide spectrum of pharmacological activities such as anti-inflammation and anticancer effects. In the last ten years, cucurbitacins had been shown to inhibit proliferation and induced apoptosis utilizing a long array of in vitro and in vivo cancer cell models. Several molecular targets for cucurbitacins have been discovered, such as fibrous-actin, signal transducer and activator of transcription (STAT), cyclooxygenase-2, etc. This review aimed at elucidating the natural sources of some cucurbitacin compounds, their chemical structure and derivatives, physical properties, biological activities and mechanism by which they reduce the proliferation human cancer cells. This widens our armaments against a devastating disease that we are failing to face.
authors.affiliation: College of Medicine, Qassim University, Kingdom of Saudi Arabia.
authors.forename: Abdullah A
authors.initials: AA
authors.lastname: Alghasham
keywords: Cucurbitacin; Janus kinase (JAK); STAT; anti-inflammation; anti-tumor; apoptosis
references.citation: Cancer Sci. 2008 Sep;99(9):1793-7
references.pmid: 18627377
references.citation: Apoptosis. 2012 Jan;17(1):79-89
references.pmid: 21928090
references.citation: Oncogene. 2005 May 5;24(20):3236-45
references.pmid: 15735720
references.citation: Cancer Res. 2002 Nov 15;62(22):6659-66
references.pmid: 12438264
references.citation: Ann N Y Acad Sci. 2006 Dec;1091:151-69
references.pmid: 17341611
references.citation: Cancer. 2002 May 1;94(9):2393-400
references.pmid: 12015764
references.citation: Oncogene. 2002 Oct 10;21(46):7001-10
references.pmid: 12370822
references.citation: J Cell Biochem. 2012 Jan;113(1):49-60
references.pmid: 21866566
references.citation: Int J Pharm. 2008 Jan 22;347(1-2):118-27
references.pmid: 17681440
references.citation: Annu Rev Biochem. 1998;67:227-64
references.pmid: 9759489
references.citation: Leuk Res. 2008 Sep;32(9):1366-73
references.pmid: 18405967
references.citation: J Pharmacol Exp Ther. 2007 Feb;320(2):581-90
references.pmid: 17065367
references.citation: Am J Pathol. 2008 Jun;172(6):1717-28
references.pmid: 18483213
references.citation: Cancer Metastasis Rev. 2005 Jun;24(2):315-27
references.pmid: 15986140
references.citation: Biochem Pharmacol. 2007 Jan 1;73(1):56-67
references.pmid: 17049494
references.citation: J Nat Prod. 2004 Nov;67(11):1823-8
references.pmid: 15568769
references.citation: Science. 1995 Mar 3;267(5202):1347-9
references.pmid: 7871432
references.citation: J Nat Prod. 2000 Sep;63(9):1300-2
references.pmid: 11000045
references.citation: Br J Cancer. 2003 Jul 21;89(2):344-9
references.pmid: 12865928
references.citation: Oncogene. 2000 May 15;19(21):2474-88
references.pmid: 10851046
references.citation: J Cell Physiol. 2003 Nov;197(2):157-68
references.pmid: 14502555
references.citation: Int J Cancer. 1999 Nov 12;83(4):564-70
references.pmid: 10508495
references.citation: Immunity. 1999 Jan;10(1):105-15
references.pmid: 10023775
references.citation: Oncogene. 2002 Mar 27;21(13):2000-8
references.pmid: 11960372
references.citation: Cell Growth Differ. 1997 Dec;8(12):1267-76
references.pmid: 9419415
references.citation: Expert Opin Drug Deliv. 2006 Jan;3(1):139-62
references.pmid: 16370946
references.citation: Environ Toxicol Pharmacol. 2012 Mar;33(2):245-51
references.pmid: 22245841
references.citation: J Pharmacol Exp Ther. 2004 May;309(2):705-10
references.pmid: 14752064
references.citation: Curr Pharm Des. 2012;18(12):1663-76
references.pmid: 22443631
references.citation: Nat Rev Immunol. 2007 Jan;7(1):41-51
references.pmid: 17186030
references.citation: Blood. 2003 Feb 15;101(4):1535-42
references.pmid: 12393476
references.citation: J Pharmacol Exp Ther. 2007 Sep;322(3):1261-8
references.pmid: 17562851
references.citation: Int J Pharm. 2008 Apr 16;354(1-2):63-9
references.pmid: 18054183
references.citation: Oncogene. 2000 Nov 16;19(48):5419-27
references.pmid: 11114718
references.citation: Biochem Biophys Res Commun. 2007 Dec 7;364(1):181-6
references.pmid: 17942079
references.citation: Br J Haematol. 2006 Oct;135(1):26-32
references.pmid: 16939498
references.citation: J Surg Res. 1997 Apr;69(1):55-60
references.pmid: 9202647
references.citation: Planta Med. 2004 May;70(5):414-20
references.pmid: 15124085
references.citation: Bioessays. 1999 Jan;21(1):47-52
references.pmid: 10070253
references.citation: Annu Rev Biochem. 1995;64:621-51
references.pmid: 7574495
references.citation: Curr Cancer Drug Targets. 2007 Feb;7(1):91-107
references.pmid: 17305481
references.citation: Front Biosci. 2008 Jan 01;13:2888-99
references.pmid: 17981761
references.citation: Cancer. 2011 Jun 15;117(12):2735-46
references.pmid: 21656752
references.citation: Anticancer Drugs. 2012 Sep;23(8):777-87
references.pmid: 22561419
references.citation: Cancer Res. 2003 Mar 15;63(6):1270-9
references.pmid: 12649187
references.citation: Biochem Pharmacol. 1984 Apr 1;33(7):995-1004
references.pmid: 6546879
references.citation: Nat Prod Rep. 2005 Jun;22(3):386-99
references.pmid: 16010347
references.citation: Eur J Cancer. 1998 Mar;34(4):503-9
references.pmid: 9713300
references.citation: Biochem Pharmacol. 2008 Jul 15;76(2):198-207
references.pmid: 18561895
references.citation: J Immunol. 2005 Apr 1;174(7):3925-31
references.pmid: 15778348
references.citation: Nat Med. 2005 Jun;11(6):595-6
references.pmid: 15937466
references.citation: Int J Oncol. 2001 Dec;19(6):1155-60
references.pmid: 11713584
references.citation: Nat Rev Cancer. 2004 Feb;4(2):97-105
references.pmid: 14964307
references.citation: Cancer Biol Ther. 2008 Aug;7(8):1243-9
references.pmid: 18487947
references.citation: Bioorg Med Chem. 2012 May 1;20(9):3016-30
references.pmid: 22472043
references.citation: Eur J Pharmacol. 2006 Feb 17;532(1-2):145-54
references.pmid: 16443215
references.citation: Oncogene. 1996 Jul 18;13(2):247-54
references.pmid: 8710363
references.citation: J Invest Dermatol. 2008 Jul;128(7):1691-5
references.pmid: 18200050
references.citation: J Clin Invest. 2002 May;109(9):1139-42
references.pmid: 11994401
references.citation: Curr Opin Cell Biol. 1997 Apr;9(2):233-9
references.pmid: 9069254
references.citation: Science. 1995 Mar 3;267(5202):1349-53
references.pmid: 7871433
references.citation: Biochem Pharmacol. 1996 Nov 22;52(10):1553-60
references.pmid: 8937470
references.citation: Oncogene. 2003 Jul 3;22(27):4150-65
references.pmid: 12833138
references.citation: Trends Genet. 1995 Feb;11(2):69-74
references.pmid: 7716810
references.citation: Cytokine Growth Factor Rev. 1997 Dec;8(4):241-52
references.pmid: 9620640
references.citation: J Nat Prod. 2012 Mar 23;75(3):444-52
references.pmid: 22239601
references.citation: Clin Cancer Res. 2003 Feb;9(2):594-600
references.pmid: 12576423
references.citation: Mol Cell Biol. 1996 Jan;16(1):369-75
references.pmid: 8524316
references.citation: Cancer Lett. 2003 Jan 10;189(1):11-6
references.pmid: 12445672
references.citation: Fitoterapia. 2005 Jul;76(5):439-41
references.pmid: 15908139
references.citation: Eur J Pharmacol. 2008 Jun 10;587(1-3):78-84
references.pmid: 18442812
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Apr 25;818(2):159-66
references.pmid: 15734155
references.citation: Oncogene. 2001 May 3;20(20):2499-513
references.pmid: 11420660
references.citation: Life Sci. 2007 Mar 20;80(15):1382-7
references.pmid: 17286991